Expanding the limits of cancer therapies
Hemerion develops novel cancer therapies that blend photonics, medecine and biotechnology. Its first breakthrough technology addresses glioblastoma as a complement to neurosurgery. Its efficacy is currently being evaluated in clinical trials.
Dr Maximilien Vermandel, Hemerion's founder, presents the news perspectives opened up by Hemerion to treat glioblastomas."